60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
GLASGOW - Scotland’s National Health Service has initiated a nationwide rollout of a genetic test designed to prevent hearing loss in newborn babies requiring antibiotic treatment, according to a press release from genedrive plc (AIM:GDR).
The Genedrive MT-RNR1 ID Kit will first be implemented at the Neonatal Intensive Care Unit at the Royal Hospital for Children in Glasgow, followed by the Royal Alexandra Hospital and Princess Royal Maternity Hospital. The program will gradually expand to all NHS Scotland Health Boards with neonatal units over the coming months.
The point-of-care genetic test identifies infants with a specific genetic variant that makes them susceptible to hearing loss when treated with certain antibiotics. By detecting this variant, healthcare providers can select alternative treatments for at-risk newborns.
"This test will have a life-changing impact on newborn babies in Scotland as we roll it out across the country through our Accelerated National Innovation Adoption pathway," said Scottish Health Secretary Neil Gray in the statement.
Dr. Helen McDevitt, Consultant Neonatologist with NHS Greater Glasgow and Clyde, noted that the "national roll out of this innovative point of care genetic test will prevent deafness in a significant number of susceptible newborn infants each year in Scotland."
The test provides results within minutes of birth, allowing for immediate adjustments to treatment plans when necessary. Ryan Coppoer, Point of Care Testing Lead in National Services Scotland, emphasized that the test aims to "safeguard their quality of life" and provide "peace of mind" to families.
The implementation represents an expansion of the test’s use after its initial introduction by NHS Greater Glasgow and Clyde.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.